These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8708744)

  • 21. Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery.
    Maltezou HC; Nikolaidis P; Lebesii E; Dimitriou L; Androulakakis E; Kafetzis DA
    Eur J Clin Microbiol Infect Dis; 2001 Sep; 20(9):643-6. PubMed ID: 11714046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Piperacillin/tazobactam: a critical review of the evolving clinical literature.
    Sanders WE; Sanders CC
    Clin Infect Dis; 1996 Jan; 22(1):107-23. PubMed ID: 8824974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of soft tissue infections with piperacillin/tazobactam.
    Tassler H; Cullmann W; Elhardt D
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():105-12. PubMed ID: 8383651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Piperacillin/tazobactam in the treatment of abdominal sepsis in patients with peritonitis].
    Gel'fand BR; Lapshina IIu; Topazova EN; Gel'fand EB
    Antibiot Khimioter; 1997; 42(2):17-20. PubMed ID: 9124988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
    File TM; Tan JS
    Eur J Surg Suppl; 1994; (573):51-5. PubMed ID: 7524796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.
    Daniel KP; Krop LC
    Pharmacotherapy; 1996; 16(2):149-62. PubMed ID: 8820460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.
    Siami G; Christou N; Eiseman I; Tack KJ;
    Antimicrob Agents Chemother; 2001 Feb; 45(2):525-31. PubMed ID: 11158750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety profile of piperacillin/tazobactam in phase I and III clinical studies.
    Kuye O; Teal J; DeVries VG; Morrow CA; Tally FP
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():113-24. PubMed ID: 8383652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis.
    Ghiselli R; Giacometti A; Cirioni O; Mocchegiani F; Orlando F; Silvestri C; Di Matteo F; Abbruzzetti A; Scalise G; Saba V
    Crit Care Med; 2008 Jan; 36(1):240-5. PubMed ID: 18090372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility of aerobic microorganisms isolated from intraabdominal infections in pediatric patients in Poland.
    Dzierzanowska-Fangrat K; Semczuk K; Łopaciuk U; Kurlenda J; Małafiej E; Puacz E; Stalmaska-Dworak E; Dzierzanowska D
    Med Sci Monit; 2005 May; 11(5):CR241-245. PubMed ID: 15874890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Niinikoski J; Havia T; Alhava E; Pääkkönen M; Miettinen P; Kivilaakso E; Haapiainen R; Matikainen M; Laitinen S
    Surg Gynecol Obstet; 1993 Mar; 176(3):255-61. PubMed ID: 8382381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia.
    Wise R
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():97-104. PubMed ID: 8383659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation.
    Philpott-Howard J; Burroughs A; Fisher N; Hastings M; Kibbler C; Mutimer D; Patch D; Rolando N; Wade J; Wendon J; O'Grady J
    J Antimicrob Chemother; 2003 Dec; 52(6):993-1000. PubMed ID: 14585863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Piperacillin/tazobactam in complicated urinary tract infections.
    Nowé P
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S39-42. PubMed ID: 7962988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. Latin American Clinical Research Group.
    Sifuentes-Osornio J; Ruíz-Palacios GM; Jakob E; Rojas JJ; Jáuregui A; Villalobos Y
    J Chemother; 1994 Jun; 6(3):197-203. PubMed ID: 7983503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections].
    Liu Y; Wang R; Yu B
    Zhonghua Yi Xue Za Zhi; 2001 Jan; 81(1):41-4. PubMed ID: 11798851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.
    Harkless L; Boghossian J; Pollak R; Caputo W; Dana A; Gray S; Wu D
    Surg Infect (Larchmt); 2005; 6(1):27-40. PubMed ID: 15865549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam.
    Peralta FG; Sánchez MB; Roíz MP; Pena MA; Tejero MA; Arjona R
    Clin Infect Dis; 2003 Dec; 37(11):1568-72. PubMed ID: 14614681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.